Background
cancer
VIRUS, SARS-COV-2 INFECTION, CANCER, DISEASE, CYTOKINE STORM
COVID-19 remains an important health problem worldwide three years after its initial description (Cytokine storm due to SARS-CoV-2 infection is a critical step in mild and severe disease (Janus Kinase (JAK) are essential proteins involved in immune response and could play a role in the hyperinflammatory state in patients with COVID19.To date, two JAK inhibitors, baricitinib and tofacitinib, have communicated positive results in randomized clinical trials (Ruxolitinib is a selective JAK 1/2 inhibitor that has shown conflicting results in COVID19. Even though several single arm studies have pointed towards a benefit with this drug, a phase III randomized trial has not confirmed such promising activity (Simvastatin is a lipid lowering agent with anti-inflammatory properties. Investigators of our group have shown that this compound can block virus internalization mediated by clatrin in cancer models (Finally, it has been proposed that patients taking simvastatin could present a more favorable outcome when developing COVID-19 (Thus, we hypothesized that the combination of ruxolitinib plus simvastatin could present a synergistic effect and prevent respiratory and clinical worsening in COVID-19 patients.As mentioned, cytokine storm seems to be the main cause of severe disease in COVID-19 (Thus, we used unsupervised clustering and machine learning methodologies to define a minimal number of cytokine determinations that could accurately identify patients at risk of severe COVID and predicted clinical deterioration 48 hours before occurring.